NYSE:CRLLife Sciences
Charles River Laboratories International (CRL) Cut 2026 Guidance, Is The Stock Still 11% Undervalued?
Charles River Laboratories International (CRL) cut its 2026 earnings guidance after reporting a second quarter net loss and slightly lower revenue. The company also continued its share repurchase program during the same period.
See our latest analysis for Charles River Laboratories International.
Despite the cut to 2026 earnings guidance and the recent quarterly net loss, Charles River Laboratories International’s share price has risen strongly over recent months, with a 30-day share price...